Related Experiment Video
Updated: Nov 11, 2025
09:43
Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
3.2K
Predictive Biomarker Panel in Proliferative Lupus Nephritis- Two-Dimensional Shotgun Proteomics
Mohsen Ghasemi, Shiva Kalantari, Roman A Zubarev
1Chronic Kidney Disease Research Center (CKDRC), Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran. shsamavat@gmail.com.
Iranian Journal of Kidney Diseases
|March 25, 2021
Summary
This study identified a panel of plasma and urine biomarkers to predict treatment response in lupus nephritis (LN). Higher inflammation markers indicate a better chance of complete remission for patients with systemic lupus erythematosus (SLE).
Area of Science:
- Nephrology
- Immunology
- Biomarker Discovery
Background:
- Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE).
- Predicting treatment response in LN is challenging due to a lack of specific clinical or laboratory indicators.
- This study aimed to identify predictive biomarkers for treatment response in LN patients before therapy initiation.
Purpose of the Study:
- To identify a panel of plasma and urine biomarkers that can predict treatment response in lupus nephritis (LN) patients.
- To differentiate patients likely to achieve complete remission versus partial remission.
Main Methods:
- LC-MS/MS analysis of plasma and urine samples from 11 biopsy-proven proliferative LN patients.
- Utilized OPLS-DA, PCA, gene ontology, and protein mapping on over 1700 proteins.
- Analyzed samples from patients achieving complete (8) and partial (3) remission.
Main Results:
- OPLS-DA successfully discriminated between complete and partial remission groups in plasma samples.
- A panel of 20 plasma and 10 urine proteins were identified as candidate biomarkers.
- These biomarkers are associated with oxidative stress, inflammation, T cell regulation, complement pathways, and kidney function.
Conclusions:
- The identified plasma and urine biomarker panel accurately discriminates patients with a high likelihood of complete treatment response.
- Elevated inflammation indices appear to correlate with a greater probability of achieving complete remission in LN patients.
